Development of a novel automated screening method for detection of FVIII Inhibitors
Authors:
- 30 January 2017
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 39 (2) , 185-190
Abstract
Summary: Introduction: Factor VIII activity is routinely determined by measuring the activated partial thromboplastin time (aPTT) of a patient plasma sample and determining percent activity from a standard curve. To maximize the detection of a clotting factor inhibitor, a subjective assessment of parallelism of a patient curve compared with a standard curve is performed. We developed and validated an automated objective method to assess parallelism as a rapid screening tool for detection of an inhibitor to factor VIII during routine FVIII assays.Methods: We performed FVIII assays on a subset of FVIII‐deficient patients with hemophilia A with and without inhibitors. Utilizing a ratio of the slopes from parallelism curves obtained by an independent Microsoft excel program in patients compared with a normal standard curve, we determined a cutoff ratio predictive for presence of an inhibitor.Results: A cutoff ratio of patient to control slopes of <0.45 for the detection of an inhibitor to FVIII was 100% sensitive and 91.6% specific, with a positive predictive value of 92.3% and a negative predictive value of 100%.Conclusion: Utilizing a ratio of the slopes from parallelism curves in patients with and without an inhibitor, we developed and validated a rapid, automated, and objective method to assess parallelism as an added screening tool for detection of an inhibitor to factor VIII during routine FVIII assays on a STAGO‐based coagulation platform. This simple automated method has the potential to detect inhibitors to other clotting factors.Keywords
Funding Information
- Livingston Trout & Mellinger Medical Research Fund
This publication has 12 references indexed in Scilit:
- Acquired hemophilia A: A concise reviewAmerican Journal of Hematology, 2005
- Inhibitors in congenital coagulation disordersBritish Journal of Haematology, 2004
- Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia AThrombosis and Haemostasis, 1998
- Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine ProteasesJournal of Biological Chemistry, 1997
- Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein CBlood, 1996
- Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIIIJournal of Biological Chemistry, 1995
- The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and ReliabilityThrombosis and Haemostasis, 1995
- A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2Blood, 1993
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).Proceedings of the National Academy of Sciences, 1988